• 1
    Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non–small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg. 2011;141:662-670.
  • 2
    Palma DA, Senan S. Improving outcomes for high-risk patients with early-stage non-small-cell lung cancer: insights from population-based data and the role of stereotactic ablative radiotherapy. Clin Lung Cancer. 2013;14:1-5.
  • 3
    Sundaresan S, McLeod R, Irish J, et al. Early results after regionalization of thoracic surgical practice in a single-payer system. Ann Thorac Surg. 2013;95:472-478.
  • 4
    Bryant AS, Rudemiller K, Cerfolio RJ. The 30- versus 90-day operative mortality after pulmonary resection. Ann Thorac Surg. 2010;89:1717-1722.
  • 5
    Haasbeek CJ, Palma D, Visser O, Lagerwaard FJ, Slotman BJ, Senan S. Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol. 2012;23:2743-2747.
  • 6
    Lou F, Huang J, Sima CS, Dycoco J, Rusch V, Bach PB. Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. J Thorac Cardiovasc Surg. 2013;145:75-81.
  • 7
    Hubbard MO, Fu P, Margevicius S, Dowlati A, Linden PA. Five-year survival does not equal cure in non–small cell lung cancer: a Surveillance, Epidemiology, and End Results-based analysis of variables affecting 10- to 18-year survival. J Thorac Cardiovasc Surg. 2012;143:1307-1313.
  • 8
    Surapaneni R, Singh P, Rajagopalan K, Hageboutros A. Stage I lung cancer survivorship: risk of second malignancies and need for individualized care plan. J Thorac Oncol. 2012;7:1252-1256.
  • 9
    Wang S, Wong ML, Hamilton N, Davoren JB, Jahan TM, Walter LC. Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. J Clin Oncol. 2012;30:1447-1455.
  • 10
    Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27:2758-2765.
  • 11
    Jorgensen TL, Hallas J, Friis S, Herrstedt J. Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality. Br J Cancer. 2012;106:1353-1360.
  • 12
    Palma DA, Senan S. Early-stage non–small cell lung cancer in elderly patients: should stereotactic radiotherapy be the standard of care? Int J Radiat Oncol Biol Phys. 2012;84:1058-1059.
  • 13
    Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol. 2012;13:802-809.
  • 14
    Wisnivesky JP, Halm E, Bonomi M, Powell C, Bagiella E. Effectiveness of radiation therapy for elderly patients with unresected stage I and II non–small cell lung cancer. Am J Respir Crit Care Med. 2010;181:264-269.
  • 15
    Lagerwaard FJ, Verstegen NE, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non–small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;83:348-353.
  • 16
    Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011;81:1352-1358.
  • 17
    Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
  • 18
    Varlotto J, Fakiris A, Flickinger J, et al. Matched-pair and propensity score comparisons of outcomes of patients with clinical stage I non–small cell lung cancer treated with resection or stereotactic radiosurgery. Cancer. 2013;119:2683-2691.
  • 19
    Osarogiagbon RU, Yu X. Mediastinal lymph node examination and survival in resected early-stage non-small-cell lung cancer in the surveillance, epidemiology, and end results database. J Thorac Oncol. 2012;7:1798-1806.
  • 20
    Verhagen AF, Schoenmakers MC, Barendregt W, et al. Completeness of lung cancer surgery: is mediastinal dissection common practice? Eur J Cardiothorac Surg. 2012;41:834-838.
  • 21
    Felip E, Rosell R, Maestre JA, et al; Spanish Lung Cancer Group. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol. 2010;28:3138-3145.
  • 22
    Verstegen NE, Oosterhuis JW, Palma DA, et al. Stage I-II non–small cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis [published online ahead of print February 20, 2013]. Ann Oncol.
  • 23
    Robinson CG, DeWees TA, El Naqa IM, et al. Patterns of failure after stereotactic body radiation therapy or lobar resection for clinical stage I non-small-cell lung cancer. J Thorac Oncol. 2013;8:192-201.
  • 24
    Luchtenborg M, Jakobsen E, Krasnik M, Linklater KM, Mellemgaard A, Moller H. The effect of comorbidity on stage-specific survival in resected non–small cell lung cancer patients. Eur J Cancer. 2012;48:3386-3395.
  • 25
    Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291:2720-2726.
  • 26
    Chow CJ, Habermann EB, Abraham A, et al. Does enrollment in cancer trials improve survival [published online ahead of print February 13, 2013]? J Am Coll Surg. pii: S1072-751501441-X. doi: 10.1016/j.jamcollsurg.2012.12.036.
  • 27
    Concato J. Is it time for medicine-based evidence? JAMA. 2012;307:1641-1643.